News

To investigate the role of the topographical distribution of temporal retinal vessels in anatomical predisposition to branch retinal vein occlusion (BRVO). Sixty patients with BRVO and 60 control ...
Central retinal vein occlusion (CRVO) is an eye condition that affects a vein in the retina. Learn about symptoms, causes, treatments, and more.
Cite this: Treatment of Branch Retinal Vein Occlusion Induced Macular Edema With Bevacizumab - Medscape - Sep 29, 2008.
There are two main types of RVO: branch retinal vein occlusion, which affects an estimated 887,000 people in the U.S. and occurs when one of the four smaller branches of the main central retinal ...
VIENNA — Adding topical squalamine to ranibizumab (Lucentis, Genentech, Inc) improves visual acuity significantly more than ranibizumab alone in patients with retinal vein occlusion, a small ...
Patients with retinal vein occlusion (RVO) were shown to have a greater risk of incident cardiovascular disease (CVD) vs unexposed patients, according to a new study published in British Journal ...
Meeting Coverage > AAO Anti-VEGF Conjugate Gets a Win in Retinal Vein Occlusion — Tarcocimab noninferior to aflibercept while cutting treatment burden in half by Charles Bankhead, Senior Editor ...
Patients with retinal vein occlusion who received Vabysmo experienced visual improvements as well as extended treatment intervals at 72 weeks, according to a study. At Angiogenesis, Exudation, and ...
The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for aflibercept injection 8mg for the treatment of macular edema ...
The European Commission approved Vabysmo for the treatment of visual impairment due to macular edema secondary to retinal vein occlusion, according to a press release from Roche.“Vabysmo is the ...